IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Malcolm Wilson MOON et al.
Title:	PRODRUGS OF 3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES
Prior Appl. No.:	10/243,942
Prior Appl. Filing Date:	09/16/2002
Examiner:	Unassigned
Art Unit:	Unassigned

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56

Mail Stop PATENT APPLICATION
Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

The USPTO has waived the requirement under 37 CFR 1.98(a)(2)(i) to submit copies of U.S. patents and U.S. patent application publications when citing and submitting an Information Disclosure Statements in a patent application filed after June 30, 2003 and in an international application that has entered the national stage under 37 USC §371 after June 30, 2003. Accordingly, copies of these types of documents are not being supplied in connection with this application. Reference is being made to Pre-OG Notice from Office of Patent Legal Administration dated July 25, 2003, *Information Disclosure Statements May Be Filed Without Copies of U.S. Patents and Published Applications in Patent Applications filed after June 30, 2003.*

Applicants submit herewith on Form PTO/SB/08 a listing of the documents cited by or submitted to the U.S. PTO in parent application Serial No. 10/243,942, filed 09/16/2002, which is a divisional of Serial No. 09/683,819, filed 05/24/2001. As provided in 37 CFR §1.98(d), copies of the documents are not being provided since they were previously

submitted to the United States Patent & Trademark Office in the above-identified parent application.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date February 10, 2004

By _____

FOLEY & LARDNER
Customer Number: 22428
Telephone: (202) 672-5475
Facsimile: (202) 672-5399

Beth A. Burrous
Attorney for Applicant
Registration No. 35,087

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 10

Complete if Known	
Prior Application Numb r	10/243,942
Prior Appl. Filing Date	09/16/2002
First Named Inventor	Malcolm Wilson MOON
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	034536-0919

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	U.S. Patent Document Kind Code[2] (*if known*)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	2,968,557		Burgandt et al.	01-17-1961	
	A2	4,002,749		Rovnyak	01-11-1977	
	A3	4,053,613		Rovnyak et al.	10-11-1977	
	A4	4,642,309		Michel et al.	02-10-1987	
	A5	5,051,417		Nadler et al.	09-24-1991	
	A6	5,124,347	A	Connor et al.	06-23-1992	
	A7	5,196,446	A	Levitzki et al.	03-23-1993	
	A8	5,302,606	A	Spada et al.	04-12-1994	
	A9	5,322,950	A	Sircar et al.	06-21-1994	
	A10	5,374,652	A	Buzzetti et al.	12-20-1994	
	A11	5,382,593	A	Le Baut et al.	01-17-1995	
	A12	5,389,661	A	Sircar et al.	02-14-1995	
	A13	5,397,787	A	Buzzetti et al.	03-14-1995	
	A14	5,409,949	A	Buzzetti et al.	04-25-1995	
	A15	5,792,783	A	Tang et al.	08-11-1998	
	A16	5,834,504	A	Tang et al.	11-10-1998	
	A17	5,849,710	A	Battistini et al.	12-15-1998	
	A18	5,880,141	A	Tang et al.	03-09-1999	
	A19	5,883,113	A	Tang et al.	03-16-1999	
	A20	5,883,116	A	Tang et al.	03-16-1999	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Prior Application Number**	10/243,942
				Prior Appl. Filing Date	09/16/2002
				First Named Inventor	Malcolm Wilson MOON
				Group Art Unit	Unassigned
(use as many sheets as necessary)				Examiner Name	Unassigned
Sheet	2	of	10	Attorney Docket Number	034536-0919

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	U.S. Patent Document Kind Code[2] (*if known*)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A21	5,886,020	A	Tang et al.	03-23-1999	
	A22	5,985,868	A	Gray	11-16-1999	
	A23	6,133,305	A	Tang et al.	10-17-2000	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (*if known*)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	A24	WO	91/13055	A2	FARMITALIA CARLO ERBA SRL	09-05-1991		
	A25	WO	92/07830	A2	PFIZER INC.	05-14-1992		
	A26	WO	92/20642	A1	RHONEPOULENC RORER INTERNATIONAL	11-26-1992		
	A27	WO	93/01182	A1	FARMITALIA CARLO ERA SRL	01-21-1993		
	A28	WO	94/14808	A1	FARMITALIA CARLO ERBA SRL	07-07-1994		
	A29	WO	95/01349	A1	FARMITALIA CARLO ERBA SRL	01-12-1995		
	A30	WO	95/17181	A1	PHARMACIA S.P.A.	06-29-1995		
	A31	WO	96/00226	A1	PHARMACIA S.P.A.	01-04-1996		
	A32	WO	96/16964	A1	PHARMACIA S.P.A.	06-06-1996		
	A33	WO	96/22976	A1	PHARMACIA S.P.A.	08-01-1996		
	A34	WO	96/32380	A1	PHARMACIA S.P.A.	10-17-1996		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 10

Complete if Known	
Prior Application Number	10/243,942
Prior Appl. Filing Dat	09/16/2002
First Named Inv ntor	Malcolm Wilson MOON
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	034536-0919

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (*if known*)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	A35	WO	96/40116	A1	SUGEN, INC.	12-19-1996		
	A36	WO	97/25986	A1	TAIHO PHARMACEUTICAL CO., LTD.	07-24-1997		
	A37	WO	98/07695	A1	SUGEN, INC.	02-26-1998		
	A38	WO	98/24432	A2	SUGEN, INC.	06-11-1998		
	A39	WO	98/38984	A2	SUGEN, INC.	09-11-1998		
	A40	WO	98/50356	A1	SUGEN, INC.	11-12-1998		
	A41	WO	99/10325	A1	GLAXO GROUP LIMITED	03-04-1999		
	A42	WO	99/52869	A1	BOEHRINGER INGELHEIM PHARMA KG	10-21-1999		
	A43	WO	99/61422	A1	SUGEN, INC.	12-02-1999		
	A44	WO	99/65869	A1	BAYER AKTIENGESELLSCHAFT	12-23-1999		
	A45	WO	00/08202	A2	SUGEN, INC.	02-17-2000		
	A46	WO	00/35906	A2	F. HOFFMAN-LA ROCHE AG	06-22-2000		
	A47	WO	00/35908	A1	F. HOFFMAN-LA ROCHE AG	06-22-2000		
	A48	WO	00/35909	A1	F. HOFFMAN-LA ROCHE AG	06-22-2000		
	A49	WO	00/38519	A1	SUGEN, INC.	07-06-2000		
	A50	WO	00/56709	A1	SUGEN, INC.	09-28-2000		
	A51	WO	01/60814	A2	SUGEN, INC.	08-23-2001		
	A52	WO	01/94624	A1	ORTHO-McNEIL PHARMACEUTICALS, INC.	12-13-2001		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 10

Complete if Known	
Prior Application Number	10/243,942
Prior Appl. Filing Date	09/16/2002
First Named Inventor	Malcolm Wilson MOON
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	034536-0919

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (*if known*)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	A53	DE	878,539		Von FREYBERG, et al.	06-05-1953		X
	A54	DE	2,159,360	A	BAYER AG	06-14-1973		X
	A55	DE	2,159,361	A	BAYER AG	06-14-1973		X
	A56	DE	2,159,362		BAYER AG	06-14-1973		
	A57	DE	2,159,363	A	BAYER AG	06-14-1973		X
	A58	DE	2,321,656	A	COLGATE-PALMOLIVE CO.	11-15-1973		X
	A59	DE	3,426,419	A	BOEHRINGER MANNHEIM GMBH	01-23-1986		X
	A60	EP	0 252 713	B1	PFIZER INC.	01-13-1988		
	A61	EP	0 351 213	A2	LES LABORATOIRES BEECHAM S.A.	01-17-1990		
	A62	EP	0 525 472	A2	FARMITALIA CARLO ERBA SRL	02-03-1993		
	A63	EP	0 632 102	A1	BAYER AG	01-04-1995		X
	A64	EP	0 662 473	A1	PHARMACIA S.P.A.	07-12-1995		
	A65	EP	0 769 947	B1	TANG, Peng Cho et al.	05-02-1997		
	A66	EP	0 788 890	A1	AGFA-GEVAERT	08-13-1997		
	A67	EP	0 934 931	A2	SUGEN, INC.	08-11-1999		
	A68	EP	1 082 305	A1	SUGEN, INC.	03-14-2001		
	A69	FR	1.398.224		IMPERIAL CHEMICAL INDUSTRIES LIMITED	05-07-1965		X
	A70	FR	1.599.772		INSTITUT PASTEUR	08-28-1970		X

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Prior Application Number	10/243,942
				Prior Appl. Filing Date	09/16/2002
				First Named Inventor	Malcolm Wilson MOON
				Group Art Unit	Unassigned
(use as many sheets as necessary)				Examiner Name	Unassigned
Sheet	5	of	10	Attorney Docket Number	034536-0919

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	A71	FR	2.689.397	A1	ADIR ET COMPAGNIE	10-08-1993		X
	A72	GB	809,691		Roy HULL	03-04-1959		
	A73	GB	835,473		Norman SENIOR	05-18-1960		
	A74	JP	62-29570	A	KANEGAFUCHI CHEM KK	02-07-1987		X
	A75	JP	62-39564	A	KANEGAFUCHI CHEM KK	02-20-1987		X
	A76	JP	63-141955	A	KANEGAFUCHI CHEM KK	06-14-1988		X
	A77	JP	5-58894	A	KANEKA CORP	03-09-1993		X
	A78	CA	2,012,634	A1	UNIVERSITY OF BRITISH COLUMBIA	09-20-1991		
	A79	AU	286870		IMPERIAL CHEMICAL INDUSTRIES OF AUSTRALIA AND NEW ZEALAND LIMITED	05-11-1967		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	A80	ANDREANI et al., "Potential Antitumor Agents. 25[1]. Synthesis and Cytotoxic Activity of 3-(2-Chloro-3-Indolymethylene)1,3-Dihydroindol-2-Ones," Anticancer Research 16:3585-3588 (1996) Elsevier, Paris	
	A81	ANDREANI et al., "Synthesis and cardiotonic activity of 2-indolinones," Eur. J. Med. Chem. 25:187-190 (1990)	
	A82	ANDREANI et al., "Synthesis and cardiotonic activity of 2-indolinones bearing pyridyl groups," Eur. J. Med. Chem. 28:653-657 (1993) Elsevier, Paris	
	A83	ANDREANI et al., "Synthesis and cardiotonic activity of pyridylmethylene-2-indolinones," Eur. J. Med. Chem. 27:167-170 (1992) 8 Elsevier, Paris	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 10

Complete if Known	
Prior Application Number	10/243,942
Prior Appl. Filing Date	09/16/2002
First Named Inventor	Malcolm Wilson MOON
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	034536-0919

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	A84	ANDREANI et al., "Synthesis and potential coanthracyclinic activity of substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones," Eur. J. Med. Chem. 32:919-924 (1997)8 Elsevier, Paris	
	A85	ANDREANI et al., "Synthesis of lactams with potential cardiotonic activity," Eur. J. Med. Chem. 28:825-829 (1993)	
	A86	ANDREANI et al., "In Vivo Cardiotonic Activity of Pyridylmethylene-2-indolinones," Arzneimittel-Forschung Drug Research 48:727-729 (1998) 8	
	A87	BAHNER and BROTHERTON, "6-Dimethylaminochrysene and Other Analogs of 4-(4-Dimethylamino)stilbene," J. Med. Chem. 12:722-723 (1969)	
	A88	BAHNER et al., "Benzylideneindenes with Oxygen Attached to the Indene Ring," J. Med. Chem. 12:721-722 (1969)	
	A89	BAMFIELD et al., "Diels-Alder Reactions of Oxindolylideneacetone," J. Chem. Soc. (C) 1028-1030 (1966) 8	
	A90	BORSCHE et al., "Über vielkernige kondensierte Systeme mit heterocyclischen Ringen. XIII.," Liebigs Ann. Chem. 550:160-174 (1941)	
	A91	BUZZETTI et al., "Cinnamamide Analogs as Inhibitors of Protein Tyrosine Kinases," Il Farmaco 48:615-636 (1993)	
	A92	CHATTEN et al., "Substituted Oxindoles. Part VI. Polarographic Reduction of Substituted *trans*-3-Benzylideneindol-2(3*H*)-ones," J. Chem. Soc. Perkin II: 469-473 (1973)	
	A93	CODA et al., "3-(4-methylbenzilidene)-1,3-dihydroindol-2-one," Journal of the Chemical Society, Perkin Transactions 2 4:615-620 (1984) DATABASE CROSSFIRE, Beilstein Reference No. 6-21	
	A94	DECODTS et al., "Suicide inhibitors of proteases. Lack of activity of halomethyl derivatives of some aromatic lactams," Eur. J. Med. Chem 18: 107-111 (1983)	
	A95	DESIMONI et al., "Catalysis with Inorganic Cations. V[1] Intramolecular Hetero Diels-Alder *versus* Ene Reactions: Effect of Magnesium perchlorate on Chemoselectivity,"Tetrahedron 52(36) 12009-12018 (1196) 8 Pergamon	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Prior Application Number**	10/243,942
				Prior Appl. Filing Dat	09/16/2002
				First Named Inventor	Malcolm Wilson MOON
				Group Art Unit	Unassigned
(use as many sheets as necessary)				Examiner Name	Unassigned
Sheet	7	of	10	Attorney Docket Number	034536-0919

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	A96	ELLIOTT and RIVERS, "Reduction of Some Oxindolylidene Derivatives to 3-Substituted Oxindoles by Sodium Borohydride," J. Med. Chem. 29:2438-2440 (1964)	
	A97	ELLIOTT et al., "1-methyl-2-(3-oxindolidenmethyl)-pyridinium," Journal of Organic Chemistry 29:2438-2440 (1964) DATABASE CROSSFIRE, Beilstein Reference No. 5-24	
	A98	GAZIT et al., "Tyrphostins. 2. Heterocyclic and α-Substituted Benzylidenemalononitrile Tyrphostins as Potent Inhibitors of EGF Receptor and ErbB2/neu Tyrosine Kinases," J. Med. Chem. 34:1896-1907 (1991) copyright Am. Clem. Soc.	
	A99	HIRAO et al., "Rhodium-Catalyzed Carbonylation of 2-Alkynylaniline: Syntheses of 1,3-Dihydroindol-2-ones," Tetrahedron Letters 36(35) 1995 8Pergamon	
	A100	HODGES et al., "Chemical and biological properties of some oxindolidyl-3-methines," Canadian J. Chemistry 46:2189-2194 (1968)	
	A101	HOWARD, Harry R., "Lactam Derivatives," U.S. Provisional Patent Application Number 60/015134	
	A102	HOWARD et al., "Synthesis and aldose reductase inhibitory activity of substituted 2(1*H*)-benzimidazolone- and oxindole-1-acetic acids," Eur. J. Med. Chem. 27:779-789 (1992) 8 Elsevier, Paris	
	A103	KATRITZKY et al., "Color and Constitution. Part 8[1]. Some Novel Dyestuffs Containing Indoxyl Residues," J. Heterocyclic Chem. 25:1287-1292 (1988)	
	A104	KOBAYASHI et al., "Anti-tumor Activity of Indole Derivatives," Yakugaku Zasshi 97:1033-1039 (1977)	
	A105	KOVAC and STETINOVA, "Furan derivatives. LXXX. Synthesis and properties of substituted furfurylidenoxindoles," Chem. rvesu 30:484-492 (1976)	
	A106	LEVITZKI and GAZIT, "Tyrosine Kinase Inhibition: An Approach to Drug Development," Science 267:1782-1788 (1995)	
	A107	MARIANI et al., "Inhibition of angiogenesis by FCE 26806, a potent tyrosine kinase inhibitor," Experimental Therapeutics - Proceedings of the American Association for Cancer Research 35:381 at abstract no. 2268 (March 1994)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 8 of 10

Complete if Known	
Prior Application Number	10/243,942
Prior Appl. Filing Dat	09/16/2002
First Named Inv ntor	Malcolm Wilson MOON
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	034536-0919

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	A108	MOHAMMADI et al., "Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors," Science 276:955-960 (1997) 8 American Association for the Advancement of Science	
	A109	NEBER and RÖCKER, "On the action of benzaldehydes on the free o-aminophenylacetic acid (II)," Chem. Ber. 56:1710-1716 (1923) (GERMAN AND ENGLISH TRANSLATION)	
	A110	NODIFF et al., "Antimalarial Phenanthrene Amino Alcohols. 3. Halogen-containing 9-phenanthrenemethanols," Chemical Abstracts, Vol. 83, abstract no. 188214 (1975)	
	A111	O'SULLIVAN and ROTHERY, "The Preparation and Possible Clinical Significance of 4'-Dialkylaminoisoindogenides," Clinica Chimica Acta 62:181-182 (1975) 8Elsevier Scientific Publishing Company	
	A112	PAVLENKO et al., "Introduction of aminomethyl groups into heterocyclic CH-acid molecules," Dopov. Akad. Nauk Ukr Rsrs, Ser. B: Geol., Khim. Biol. Nauki 7:64-66 (1980) We should add thqat we are Sub. Abstract	
	A113	PLOWMAN et al., "Receptor Tyrosine Kinases as Targets for Drug Intervention," DN&P 7:334-339 (1994)	
	A114	QUALLICH et al., Á General Oxindole Synthesis," J. Synthetic Organic Chemistry: 51-51 (1993)	
	A115	SCHUCHTER et al., "Successful Treatment of Murine Melanoma with Bryostatin 1," Cancer Research 51:682-687 (1991)	
	A116	SHIRAISHI et al., "Specific inhibitors of Tyrosine-Specific Protein Kinase, Synthetic 4-Hydroxycinnamamide Derivatives," Biochemical and Biophysical Research Communications 147:322-328 (1987)8 Academic Press	
	A117	SHIRAISHI et al., "Specific Inhibitors of Tyrosine-specific Protein Kinases: Properties of 4-Hydroxycinnamamide Derivatives in Vitro," Cancer Research 49:2374-2378 (1989)	
	A118	SINGH et al., "Indolinone Derivatives as Potential Antimicrobial Agents," Zentralbl. Mikrobiol. 144:105-109 (1989) copyright VEB Gustav Fischer Veriag Jena	
	A119	SPADA, et al., "Small molecule inhibitors of tyrosine kinase activity," Expert Opinion on Therapeutic Patents 5:805-817 (1995) 8Ashley Publications	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 9 of 10

Complete if Known	
Prior Application Number	10/243,942
Prior Appl. Filing Date	09/16/2002
First Named Inventor	Malcolm Wilson MOON
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	034536-0919

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	A120	SUN et al., "Design, Synthesis, and Evaluations of Substituted 3-[(3- or 4-Carboxyethylpyrrol-2-yl) methylidenyl]indolin-2-ones as Inhibitors of VEGF, FGF, and PDGF Receptor Tyrosine Kinases," Journal of Medicinal Chemistry 42: 5120-5130 (1999) 8American Chemical Society	
	A121	SUN et al, "Synthesis and Biological Evaluations of 3-Substituted Indolin-2-ones: A Novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particular Receptor Tyrosine Kinases," J. Med. Chem. 41:2588-2603 (1998) 8The American Chemical Society	
	A122	TACCONI and MARINONE, "Preparazione e caratteristiche di alcuni 3-ossindolidenderivati," Ricerca Scientifica 38:1239-1244 (1968)	
	A123	TACCONI et al., "(Z)- and (E)-3-Alkylidene-1,3-dihydroindol-2-ones: Influence of Configuration on the Transmission of the Inductive Effect to the Carbonyl Group," J.C.S. Perkin II 150-154 (1976)	
	A124	THOMPSON et al., "Facile Dimerisation of 3-Benzylideneindoline-2-thiones," J. Chem. Soc. Perkin Trans. (I) 1835-1837 (1993)	
	A125	TRAXLER, "Protein tyrosine kinase inhibitors in cancer treatment," Expert Opinion on Therapeutic Patents 7(6):571-588 (1997) 8 Ashley Publications Ltd.	
	A126	WAHL et al., "3-benzilidene-5-methyl-1,3-dihydroindol-2-one," Ann. Chim. 350 (1926), DATABASE CROSSFIRE, Beilstein Reference No. 2-21-00-00290	
	A127	WAHL et al., "Chimie Organique - Sur les iso-indogenides," C.R. Hebd. Seances Acad. Sci. 149:132-134 (1909)	
	A128	WAHL, Beilstein Reg. No. 191439, Bull. Soc. Chim. Fr., page 1038 (1909)	
	A129	WAHL, Beilstein Reg. No. 231732, Bull. Soc. Chim. Fr., pages 1035-1038 (1909)	
	A130	WALKER et al., "Synthesis of New 3-(Pyridylmethylene)-, 3-(Pyridylmethyl)-, 3-(Piperidylmethyl)-, and 3-(β-Alkylaminoethyl)-2-indolinones. The Reduction of Isoindogenides, Nitro Compounds, and Pyridines in a Series of 2-Indolinones," J. Med. Chem. 8:626-637 (1965)	
	A131	WRIGHT et al., "Cyclic Hydroxamic Acids Derived from Indole," J. Am. Chem. Soc. 78:221-224 (1956)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	10	of	10

Complete if Known	
Prior Application Number	10/243,942
Prior Appl. Filing Dat	09/16/2002
First Named Inventor	Malcolm Wilson MOON
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	034536-0919

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	A132	WRIGHT et al., "Inhibition of Angiogenesis in Vitro and In Ovo With an Inhibitor of Cellular Protein Kinases, MDL 27032," J. Cellular Physiology 152:448-457 (1992)	
	A133	ZHANG et al., "Microtubule Effects of Welwistatin, a Cyanobacterial Indolinone that Circumvents Multiple Drug Resistance," Molecular Pharmacology 49:228-234 (1996) 8The American Society for Pharmacology and Experimental Pharmaceutics	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.